TAKHZYRO
PeakmAblanadelumab-flyo
BLASUBCUTANEOUSSOLUTIONPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
TAKHZYRO (lanadelumab-flyo) is kallikrein inhibitors [moa]. First approved in 2018.
Drug data last refreshed 7m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAKHZYRO (lanadelumab-flyo) is a monoclonal antibody that inhibits plasma kallikrein, a key enzyme in the bradykinin-generating pathway. It is approved for the treatment of hereditary angioedema (HAE) in patients with inadequate control on prophylactic therapy or those unable to tolerate other treatments. The drug provides subcutaneous prophylaxis to reduce the frequency and severity of HAE attacks.
$6.0MPart D
PeakPeak lifecycle stage with modest Part D penetration ($6M, 147 claims in 2023) indicates a niche rare disease product with established market presence and stable commercial infrastructure.
Mechanism of Action
Kallikrein Inhibitors
Pharmacologic Class:
Plasma Kallikrein Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea
Started Oct 2026
35 enrolled
Hereditary Angioedema (HAE)
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
Started Jul 2024
115 enrolled
Hereditary Angioedema (HAE)
Career Relevance
TAKHZYRO offers career opportunities in rare disease commercialization, requiring deep specialist knowledge of HAE diagnosis, patient pathways, and payer dynamics. Roles emphasize consultative selling, strong HCP relationships, and reimbursement expertise in a niche but established market.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.